3:17
Anti-BCMA CAR T-cells for MM: durable clinical responses with bb2121
Yi Lin
1:46
Next-generation CAR T-cell products for 2018
Yi Lin
2:38
Prophylactic treatment for CAR T-cell toxicity shows promising results
Yi Lin
2:00
ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel
Yi Lin
9:48
The use of CAR T-cells in multiple myeloma
Adam Cohen et al.
2:24
ZUMA-1: a pivotal trial of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with NHL
Yi Lin
3:58
ZUMA-1: a pivotal trial of CAR T-cells in NHL
Yi Lin
3:14
bb2121: bringing CAR T-cells into the multiple myeloma world
Yi Lin
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals